Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Docetaxel and S-1 for Advanced Esophageal Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Hallym University Medical Center
Jeil Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Hallym University Medical Center Identifier:
First received: September 20, 2012
Last updated: September 27, 2016
Last verified: September 2016
This study will evaluate the efficacy of docetaxel and S-1 combination chemotherapy in Korean patients with esophageal cancer.

Condition Intervention Phase
Esophageal Neoplasms
Drug: DS (docetaxel+S-1)
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Docetaxel and S-1 as First-line Chemotherapy in Patients With Advanced Esophageal Cancer

Resource links provided by NLM:

Further study details as provided by Hallym University Medical Center:

Primary Outcome Measures:
  • Objective response rate [ Time Frame: 1.5 years ]

Secondary Outcome Measures:
  • Progression free survival [ Time Frame: 1.5 years ]
  • Overall survival [ Time Frame: 1.5 years ]
  • Toxicity profiles [ Time Frame: 1.5 years ]
  • Disease control rate [ Time Frame: 1.5 years ]

Estimated Enrollment: 37
Study Start Date: November 2011
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DS (docetaxel+S-1)

Treatment will be delivered as a 3-week cycle.

  1. Docetaxel 60 mg/m²IV on day 1
  2. S-1 80 mg/m2/day PO on day 1-14
Drug: DS (docetaxel+S-1)

Treatment will be delivered as a 3-week cycle.

  1. Docetaxel 60 mg/m²IV on day 1
  2. S-1 80 mg/m2/day PO on day 1-14
Other Names:
  • Taxotere
  • TS-1

Detailed Description:

Esophageal cancer is the ninth most common cancer in male population in Korea. It was estimated that 1,864 new cases of esophageal cancer were reported and 1,434 deaths occurred in Korea in 2005.

Although half of the patients with esophageal cancer initially present with locoregional disease amenable to radical surgery or radiation-based therapy, most patients eventually develop metastatic disease with or without local recurrence.

Chemotherapy plays a major role in palliative therapy and remains to be the primary mode of treatment for the recurrent or metastatic esophageal cancer. Although various chemotherapy regimens are available, esophageal cancer carries a very poor prognosis, with a mean survival time of less than 8.1 months with current chemotherapies used singly or in combination with 5-fluorouracil (5-FU), vindesine, mitomycin, docetaxel, paclitaxel, cisplatin, irinotecan, vinorelbine, or capecitabine. The majority of the trials performed were in small numbers of patients with reported response rates from 15 to 40%.

The response was usually of short duration and there was no survival benefit with single agent chemotherapy. Combination chemotherapy has slightly improved the results in terms of duration of response (3-6 months), but still there was little improvement in overall survival. Therefore, the identification of new active agents is essential to prolong the survival.

Clinical trials of single agent docetaxel have been reported in patients with esophageal cancer and the response rate is about 18-25%.

S-1, a new biochemical modulator of 5-FU, is an oral dihydropyrimidine dehydrogenase(DPD) inhibitory fluoropyrimidine. The advantages of S-1 compared with 5-FU are greater convenience because of its oral formulation and continuous delivery, without intravenous infusion. S-1 is frequently used as a substitute for 5-FU in gastric cancer, but limited data is available for esophageal cancer.

The combination of docetaxel and S-1 is highly active and well tolerated in advanced or recurrent gastric cancer, and the synergistic antitumor activity has been fully elucidated.

Therefore, we will evaluate the efficacy of docetaxel and S-1 combination chemotherapy in Korean patients with esophageal cancer.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pathologically confirmed squamous cell carcinoma or adenocarcinoma of esophagus.
  • Unresectable locally advanced, recurrent or metastatic disease.
  • Measurable or evaluable disease by RECIST criteria 1.1.
  • Minimum age of 18 years.
  • ECOG Performance status 0-2.
  • Prior chemotherapy is not allowed.
  • More than 4 weeks since completion of prior radiotherapy (measurable or evaluable lesions are outside the radiation field)
  • Adequate organ functions
  • Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital

Exclusion Criteria:

  • Other tumor type than squamous cell carcinoma and adenocarcinoma
  • Previous history of chemotherapy except neoadjuvant or adjuvant chemotherapy without docetaxel and S-1
  • Obvious bowel obstruction unrelieved by proper management
  • Evidence of serious gastrointestinal bleeding
  • Patients with CNS metastases
  • Patients with active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus, myocardial infarction during the preceding 6 months, pregnancy, or breast feeding
  • Any previous or concurrent malignancy other than non-melanoma skin cancer or in situ cancer of uterine cervix
  • Known history of cerebral or leptomeningeal metastases or neurologic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01693432

Contact: Dae Young Zang, MD, PhD 82313803871
Contact: Jin Hee Jung, RN 82313803704

Korea, Republic of
Hallym University Medical Center Recruiting
Anyang, Korea, Republic of
Contact: Dae Young Zang, MD, PhD    82313803871   
Contact: Jin Hee Jung, RN    82313803704   
Sub-Investigator: Hyeong Su Kim, MD         
Sub-Investigator: Boram Han, MD         
Sponsors and Collaborators
Hallym University Medical Center
Jeil Pharmaceutical Co., Ltd.
Principal Investigator: Dae Young Zang, MD, PhD Hallym University Medical Center
  More Information

Responsible Party: Hallym University Medical Center Identifier: NCT01693432     History of Changes
Other Study ID Numbers: HMC-HO-GI-1202
Study First Received: September 20, 2012
Last Updated: September 27, 2016
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by Hallym University Medical Center:
Esophageal neoplasms

Additional relevant MeSH terms:
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017